ROS1 and non-small cell lung carcinoma: In a lately single arm phase I/II trial screening 69 ROS1 positive NSCLC sufferers (30% ROS1 TKI naive, 58% earlier treated with crizotinib and 12% treated with one, non-crizotinib ROS1 TKI or more than 2 ROS1 TKIs), an overwhelming 57% of treated individuals exhibited brain metastases at baseline with 41% ORR amongst all.